U.S. Markets open in 5 hrs 36 mins

Bio-Path Holdings, Inc. (BPTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4292-0.05 (-9.85%)
At close: 4:00PM EDT
People also watch

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard
Suite 210
Bellaire, TX 77401
United States

IndustryDrug Delivery
Full Time Employees12

Key Executives

Mr. Peter H. Nielsen MBACo-Founder, Chairman, CEO, Pres, CFO and Treasurer596.46kN/A68
Dr. Ulrich W. Mueller Ph.D.Chief Operating Officer and Sec.406.3kN/A50
Dr. Ana Tari Ashizawa Ph.D., MBADirector of ResearchN/AN/AN/A
Dr. Suzanne Kennedy Ph.D.Director of Corp. Devel.N/AN/AN/A
Ms. Tara Sadeghi M.P.HDirector of Clinical OperationsN/AN/A56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Corporate Governance

Bio-Path Holdings, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.